Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s

Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.